Evaluation of some pharmaceutical aspects of intrathecal methotrexate sodium, cytarabine and hydrocortisone sodium succinate
- PMID: 25579
Evaluation of some pharmaceutical aspects of intrathecal methotrexate sodium, cytarabine and hydrocortisone sodium succinate
Abstract
Methotrexate sodium, cytarabine and hydrocortisone sodium succinate were evaluated in three vehicles, Sodium Chloride Injection, USP, Lactated Ringer's Injection, USP, and Elliott's B solution, an artificial cerebrospinal fluid (CSF). Osmolarity values of all drug solutions studied were within 10% of normal human. No vehicle-related alterations in the stability of methotrexate or cytarabine were detected under simulated use conditions. However, the degradation of hydrocortisone sodium succinate was faster in Elliott's B solution than in the other vehicles. Principal differences among the vehicles involved electrolyte content, pH and buffer capacity. Elliott's B solution is similar to CSF in electrolyte composition and buffer capacity, and was the only vehicle to maintain the pH of dilute methotrexate and cytarabine solutions between 7.2 and 7.8. The significance of these in vitro data await a careful clinical study.
Similar articles
-
Evaluation of osmolality and pH of various concentrations of methotrexate, cytarabine, and thiotepa prepared in normal saline, sterile water for injection, and lactated Ringer's solution for intrathecal administration.J Oncol Pharm Pract. 2009 Mar;15(1):45-52. doi: 10.1177/1078155208096902. Epub 2008 Sep 4. J Oncol Pharm Pract. 2009. PMID: 18772215 Review.
-
Stability of cytarabine, methotrexate sodium, and hydrocortisone sodium succinate admixtures.Am J Hosp Pharm. 1984 Sep;41(9):1802-6. Am J Hosp Pharm. 1984. PMID: 6496516
-
Stability of four standardized preparations of methotrexate, cytarabine, and hydrocortisone for intrathecal use.J Oncol Pharm Pract. 2016 Oct;22(5):659-65. doi: 10.1177/1078155215600905. Epub 2015 Aug 12. J Oncol Pharm Pract. 2016. PMID: 26271105
-
Stability of extemporaneously prepared cytarabine, methotrexate sodium, and methylprednisolone sodium succinate.Am J Health Syst Pharm. 2012 Feb 1;69(3):232-40. doi: 10.2146/ajhp110208. Am J Health Syst Pharm. 2012. PMID: 22261946
-
Intrathecal injections--a review of pharmaceutical factors.Bull Parenter Drug Assoc. 1977 Sep-Oct;31(5):237-47. Bull Parenter Drug Assoc. 1977. PMID: 21718 Review. No abstract available.
Cited by
-
Evaluation of standardized triple intrathecal therapy toxicity in oncohematological pediatric patients.Int J Clin Pharm. 2017 Feb;39(1):126-132. doi: 10.1007/s11096-016-0408-0. Epub 2016 Dec 8. Int J Clin Pharm. 2017. PMID: 27933487
-
Preventing acute neurotoxicity of CNS therapeutic oligonucleotides with the addition of Ca2+ and Mg2+ in the formulation.Mol Ther Nucleic Acids. 2024 Oct 15;35(4):102359. doi: 10.1016/j.omtn.2024.102359. eCollection 2024 Dec 10. Mol Ther Nucleic Acids. 2024. PMID: 39554992 Free PMC article.
-
Stability of solutions of antineoplastic agents during preparation and storage for in vitro assays. III. Antimetabolites, tubulin-binding agents, platinum drugs, amsacrine, L-asparaginase, interferons, steroids and other miscellaneous antitumor agents.Cancer Chemother Pharmacol. 1989;23(4):197-207. doi: 10.1007/BF00451642. Cancer Chemother Pharmacol. 1989. PMID: 2466580 Review.